Biochemical Genetics

, Volume 54, Issue 4, pp 413–420 | Cite as

The Value of miR-299-5p in Diagnosis and Prognosis of Intestinal-Type Gastric Adenocarcinoma

  • Shirin Azarbarzin
  • Mohammad Ali Hosseinpour FeiziEmail author
  • Reza Safaralizadeh
  • Reyhaneh Ravanbakhsh
  • Mina Kazemzadeh
  • Alavieh Fateh
  • Nasibeh Karimi
  • Yaghoub Moaddab
Original Article


MicroRNAs (miRNAs) are a class of non-coding RNAs, containing about 22 nucleotides and having a pivotal function in various cellular processes. The oncogenic and tumor suppressor roles of miRNAs have been identified in cancers especially in gastric cancer, which is one of the most prevalent cancers. MiR-299-5p is located in the imprinted Dlk1-Dio3 region in chromosome 14q32. Aberrant expression of miR-299-5p was determined in solid and blood cancers. The current study was performed to assess the expression pattern of miR-299-5p in intestinal-type gastric adenocarcinoma and compare it with the normal adjacent counterparts. The expression level of miR-299-5p was investigated in forty fresh specimens which were obtained from gastric cancer patients during endoscopy. Moreover, the association of aberrant expression of miR-299-5p and clinicopathological features, as well as the susceptibility of miR-299-5p as a tumor marker, was determined. The result of qRT-PCR revealed the downregulation of miR-299-5p in intestinal-type gastric adenocarcinoma compared with adjacent tumor-free tissues (P < 0.001); this misregulation can be used as a tumor marker. Analysis of miR-299-5p misregulation did not reveal a significant correlation with clinical features. The result obtained from the present study revealed the significant downregulation of miR-299-5p in intestinal-type gastric adenocarcinoma which is consistent with previous studies showing miR-299-5p downregulation in other types of cancers. The data obtained from the current study suggest basic information which can be very helpful for future research in the field of diagnosis and treatment of gastric cancer.


miRNA miR-299-5p qRT-PCR Intestinal-type gastric adenocarcinoma 



We would like to thank the patients, staff, and nurses in the Endoscopy and the pathology Department of Tabriz Imam Reza hospital who sincerely helped us in conducting this project.

Compliance with Ethical Standards

Conflict of interest

There is no conflict of interest.


  1. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S (2000) Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89(7):1418–1424. doi: 10.1002/1097-0142(20001001)89:7<1418:AID-CNCR2>3.0.CO;2-A CrossRefPubMedGoogle Scholar
  2. Alimov A, Sundelin B, Wang N, Larsson C, Bergerheim U (2004) Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol 25(1):179–185. doi: 10.3892/ijo.25.1.179 PubMedGoogle Scholar
  3. Bae S, Lee EM, Cha HJ, Kim K, Yoon Y, Lee H, An S (2011) Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells. Mol Cells 32(3):243–249. doi: 10.1007/s10059-011-1037-z CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Garcia-Foncillas J (2006) Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5:29. doi: 10.1186/1476-4598-5-29 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E (2013) The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci 70(5):795–814. doi: 10.1007/s00018-012-1080-8 CrossRefPubMedGoogle Scholar
  6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Croce CM (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9):2999–3004. doi: 10.1073/pnas.0307323101 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Carcas LP (2014) Gastric cancer review. J Carcinog 13:14. doi: 10.4103/1477-3163.146506 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Courts C, Madea B (2010) Micro-RNA—a potential for forensic science? Forensic Sci Int 203(1–3):106–111. doi: 10.1016/j.forsciint.2010.07.002 CrossRefPubMedGoogle Scholar
  9. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Tuschl T (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141(1):129–141. doi: 10.1016/j.cell.2010.03.009 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Jeggari A, Marks DS, Larsson E (2012) miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 28(15):2062–2063. doi: 10.1093/bioinformatics/bts344 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61(2):69–90. doi: 10.3322/caac.20107 CrossRefGoogle Scholar
  12. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13(6):e249–e258. doi: 10.1016/s1470-2045(12)70073-6 CrossRefPubMedGoogle Scholar
  13. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, Siegal T (2010) Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 12(5):422–433. doi: 10.1093/neuonc/nop061 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Kerin MJ (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11(3):R27. doi: 10.1186/bcr2257 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009) Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 12(6):576–583PubMedGoogle Scholar
  16. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117(4):1121–1129. doi: 10.1182/blood-2010-09-191312 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z (2009) Cancer incidence and mortality in Iran. Ann Oncol 20(3):556–563. doi: 10.1093/annonc/mdn642 CrossRefPubMedGoogle Scholar
  18. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J (2004) A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 14(9):1741–1748. doi: 10.1101/gr.2743304 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Shevde LA, Samant RS (2014) Role of osteopontin in the pathophysiology of cancer. Matrix Biol 37:131–141. doi: 10.1016/j.matbio.2014.03.001 CrossRefPubMedGoogle Scholar
  20. Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS (2010) Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 14(6b):1693–1706. doi: 10.1111/j.1582-4934.2009.00821.x CrossRefPubMedGoogle Scholar
  21. Somi MH, Golzari M, Farhang S, Naghashi S, Abdollahi L (2014) Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev 15(9):3945–3949CrossRefPubMedGoogle Scholar
  22. Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Zhu Z (2013) Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci 9(1):55–66. doi: 10.7150/ijbs.5280 CrossRefPubMedGoogle Scholar
  23. Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, McKay MJ, Fox SB (2012) Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Res 14(2):R69. doi: 10.1186/bcr3176 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Leibowitz-Amit R (2012) Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer 11:44. doi: 10.1186/1476-4598-11-44 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Shirin Azarbarzin
    • 1
  • Mohammad Ali Hosseinpour Feizi
    • 1
    Email author
  • Reza Safaralizadeh
    • 1
  • Reyhaneh Ravanbakhsh
    • 1
  • Mina Kazemzadeh
    • 1
  • Alavieh Fateh
    • 1
  • Nasibeh Karimi
    • 1
  • Yaghoub Moaddab
    • 2
  1. 1.Department of Animal Biology, Faculty of Natural SciencesUniversity of TabrizTabrizIran
  2. 2.Liver and Gastroenterology Diseases Research CenterTabriz University of Medical SciencesTabrizIran

Personalised recommendations